BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W, Guo RP, Shi M. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer. 2017;36:83. [PMID: 29061175 DOI: 10.1186/s40880-017-0251-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Hou Z, Liu J, Jin Z, Qiu G, Xie Q, Mi S, Huang J. Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends 2022. [PMID: 35173139 DOI: 10.5582/bst.2022.01044] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kong SY, Song JJ, Jin YQ, Deng MJ, Yan JX. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Acta Clin Belg 2022;:1-9. [PMID: 35587164 DOI: 10.1080/17843286.2022.2076791] [Reference Citation Analysis]
3 Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol 2021;:JCO2100608. [PMID: 34648352 DOI: 10.1200/JCO.21.00608] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
4 He M, Li Q, Shi M. Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma-In Reply. JAMA Oncol 2019;5:1806-7. [PMID: 31600361 DOI: 10.1001/jamaoncol.2019.4058] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
6 He M, Li Q, Shen J, Tan G, Li Q, Lai J, Wei W, Zhang Y, Zou R, Chen M, Guo R, Shi M. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. Cancer Med 2019;8:4200-13. [PMID: 31207163 DOI: 10.1002/cam4.2355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
7 Mei J, Lin WP, Shi F, Wei W, Liang JB, Shi M, Zheng L, Li SH, Guo RP. Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy. Eur J Radiol 2021;142:109890. [PMID: 34375811 DOI: 10.1016/j.ejrad.2021.109890] [Reference Citation Analysis]
8 Zhang H, Chen R, Wang X, Zhang H, Zhu X, Chen J. Lobaplatin-Induced Apoptosis Requires p53-Mediated p38MAPK Activation Through ROS Generation in Non-Small-Cell Lung Cancer. Front Oncol 2019;9:538. [PMID: 31428569 DOI: 10.3389/fonc.2019.00538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Long GB, Xiao CW, Zhao XY, Zhang J, Li X. Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2020;99:e20745. [PMID: 32590750 DOI: 10.1097/MD.0000000000020745] [Reference Citation Analysis]
10 Zhou ZG, Chen JB, Zhang RX, Ye L, Wang JC, Pan YX, Wang XH, Li WX, Zhang YJ, Xu L, Chen MS. Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients. Cancer Commun (Lond) 2020;40:355-69. [PMID: 32609436 DOI: 10.1002/cac2.12069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Gao J, Zhen R, Liao H, Zhuang W, Guo W. Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma. Oncol Lett. 2018;15:7175-7181. [PMID: 29725440 DOI: 10.3892/ol.2018.8242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Huang J, Huang W, Zhan M, Guo Y, Liang L, Cai M, Lin L, He M, Lian H, Lu L, Zhu K. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1445-58. [PMID: 34858889 DOI: 10.2147/JHC.S339379] [Reference Citation Analysis]
13 Zhu Y, Sun P, Wang K, Xiao S, Cheng Y, Li X, Wang B, Li J, Yu W, Cheng Y. Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China. Cancer Cell Int 2021;21:503. [PMID: 34537075 DOI: 10.1186/s12935-021-02200-7] [Reference Citation Analysis]
14 Guo Z, Wang J, Li L, Liu R, Fang J, Tie B. Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. World J Clin Cases 2020; 8(16): 3493-3502 [PMID: 32913856 DOI: 10.12998/wjcc.v8.i16.3493] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ke Q, Wang L, Wu W, Huang X, Li L, Liu J, Guo W. Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma. Front Oncol 2021;11:720079. [PMID: 35004268 DOI: 10.3389/fonc.2021.720079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Liu B, Zhu X, Gao S, Guo J, Wang X, Cao G, Zhu L, Liu P, Xu H, Chen H, Zhang X, Liu S, Kou F. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma. J Interv Med 2019;2:91-6. [PMID: 34805879 DOI: 10.1016/j.jimed.2019.07.006] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Chen J, Lu S, Zhang Y, Xu L, Chen J, Wang J, Chen M, Zhang R, Zhou Z. Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis. J Cancer. 2018;9:1745-1753. [PMID: 29805700 DOI: 10.7150/jca.24568] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
18 Li B, Qiu J, Zheng Y, Shi Y, Zou R, He W, Yuan Y, Zhang Y, Wang C, Qiu Z, Li K, Zhong C, Yuan Y. Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma. Annals of Surgery Open 2021;2:e057. [DOI: 10.1097/as9.0000000000000057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Liang RB, Zhao Y, He MK, Wen DS, Bu XY, Huang YX, Lai ZC, Xu YJ, Kan A, Wei W, Zhang YJ, Chen MS, Guo RP, Li QJ, Shi M. Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. Front Oncol 2021;11:619461. [PMID: 34055599 DOI: 10.3389/fonc.2021.619461] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Liu S, Lai J, Lyu N, Xie Q, Cao H, Chen D, He M, Zhang B, Zhao M. Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy. Front Oncol 2020;10:582504. [PMID: 33614477 DOI: 10.3389/fonc.2020.582504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Xin Y, Cao F, Yang H, Zhang X, Chen Y, Cao X, Zhou X, Li X, Zhou J. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Front Immunol 2022;13:929141. [DOI: 10.3389/fimmu.2022.929141] [Reference Citation Analysis]
22 He MK, Zou RH, Wei W, Shen JX, Zhao M, Zhang YF, Lin XJ, Zhang YJ, Guo RP, Shi M. Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. J Vasc Interv Radiol 2018;29:1068-1077.e2. [PMID: 30042075 DOI: 10.1016/j.jvir.2018.03.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
23 Zhang J, Zhang X, Mu H, Yu G, Xing W, Wang L, Zhang T. Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. Front Oncol 2021;11:729764. [PMID: 34868921 DOI: 10.3389/fonc.2021.729764] [Reference Citation Analysis]
24 Yuan H, Lu H, Zeng J, Zhang Y, Shen L. Comparison of radiation doses between hepatic artery infusion chemotherapy and transarterial chemoembolization for liver cancer. Journal of Interventional Medicine 2021;4:184-9. [DOI: 10.1016/j.jimed.2021.08.004] [Reference Citation Analysis]
25 Li W, Pei Y, Wang Z, Liu J. Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Front Oncol 2022;12:930868. [DOI: 10.3389/fonc.2022.930868] [Reference Citation Analysis]
26 Zhao Y, He M, Liang R, Li Q, Shi M. Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin. Ther Clin Risk Manag 2021;17:73-7. [PMID: 33519205 DOI: 10.2147/TCRM.S283192] [Reference Citation Analysis]
27 Hsu SJ, Xu X, Chen MP, Zhao ZY, Wang Y, Yin X, Zhang L, Ge NL, Chen Y, Wang YH, Luo JF, Ren ZG, Chen RX. Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. Acad Radiol 2021;28 Suppl 1:S157-66. [PMID: 33653656 DOI: 10.1016/j.acra.2021.01.024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Xu L, Chen L, Zhang W. Neoadjuvant treatment strategies for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(12): 1550-1566 [DOI: 10.4240/wjgs.v13.i12.1550] [Reference Citation Analysis]
29 Jonas E, Bernon M, Robertson B, Kassianides C, Keli E, Asare KO, Alatise IO, Okello M, Blondel NO, Mulehane KO, Abubeker ZA, Nogoud AA, Nashidengo PR, Chihaka O, Tzeuton C, Dusheiko G, Sonderup M, Spearman CW. Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00042-5] [Reference Citation Analysis]
30 Li S, Deng M, Wang Q, Mei J, Zou J, Lin W, Shi M, Chen M, Wei W, Guo R. Transarterial Infusion Chemotherapy with FOLFOX Could be an Effective and Safe Treatment for Unresectable Intrahepatic Cholangiocarcinoma. J Oncol 2022;2022:2724476. [PMID: 35342396 DOI: 10.1155/2022/2724476] [Reference Citation Analysis]
31 Li S, Lyu N, Han X, Li J, Lai J, He M, Deng H, Shi M, Wang H, Zhao M. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. J Vasc Interv Radiol 2021;32:1267-1276.e1. [PMID: 34166806 DOI: 10.1016/j.jvir.2021.06.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 He MK, Liang RB, Zhao Y, Xu YJ, Chen HW, Zhou YM, Lai ZC, Xu L, Wei W, Zhang YJ, Chen MS, Guo RP, Li QJ, Shi M. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol 2021;13:17588359211002720. [PMID: 33854567 DOI: 10.1177/17588359211002720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Li S, Mei J, Wang Q, Guo Z, Lu L, Ling Y, Xu L, Chen M, Zheng L, Lin W, Zou J, Wen Y, Wei W, Guo R. Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial. Ann Surg Oncol 2020;27:5183-90. [PMID: 32418078 DOI: 10.1245/s10434-020-08601-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Mei J, Li SH, Li QJ, Sun XQ, Lu LH, Lin WP, Zheng L, Chen MS, Shi M, Wei W, Guo RP. Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:167-76. [PMID: 33791252 DOI: 10.2147/JHC.S298538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Cai Z, He C, Zhao C, Lin X. Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma. Front Oncol 2021;11:611118. [PMID: 33868997 DOI: 10.3389/fonc.2021.611118] [Reference Citation Analysis]
36 Li S, Mei J, Wang Q, Shi F, Liu H, Zhao M, Lu L, Ling Y, Guo Z, Guo Y, Chen X, Shi M, Lau WY, Wei W, Guo R. Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice. Hepatobiliary Surg Nutr 2021;10:631-45. [PMID: 34760967 DOI: 10.21037/hbsn.2020.03.14] [Reference Citation Analysis]
37 Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH, Lin XJ, Xu L, Shi M, Zheng L, Chen MS, Guo RP. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond) 2018;38:61. [PMID: 30305149 DOI: 10.1186/s40880-018-0331-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
38 Hong H, Jianwei J, Qinhua W, Yunjuan Y, Chen G, Jiaqin L. Effects of Interventional Therapy on Liver Metastases-Measurement of Liver Volume by Abdominal Computed Tomography. j med imaging hlth inform 2021;11:2040-3. [DOI: 10.1166/jmihi.2021.3660] [Reference Citation Analysis]